PNC Financial Services Group’s Clearside Biomedical CLSD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-7,194
Closed -$28.6K 5188
2025
Q3
$28.6K Sell
7,194
-1
-0% -$7 ﹤0.01% 3487
2025
Q2
$86.3K Hold
7,195
﹤0.01% 2808
2025
Q1
$99.1K Sell
7,195
-21
-0.3% -$302 ﹤0.01% 2667
2024
Q4
$103K Buy
7,216
+21
+0.3% +$345 ﹤0.01% 2664
2024
Q3
$137K Buy
7,195
+6,823
+1,834% +$116K ﹤0.01% 2470
2024
Q2
$7.26K Hold
372
﹤0.01% 3889
2024
Q1
$8.55K Hold
372
﹤0.01% 3805
2023
Q4
$6.54K Hold
372
﹤0.01% 3866
2023
Q3
$4.86K Hold
372
﹤0.01% 4003
2023
Q2
$6.26K Hold
372
﹤0.01% 4048
2023
Q1
$5.81K Hold
372
﹤0.01% 3990
2022
Q4
$6.26K Hold
372
﹤0.01% 3920
2022
Q3
$6K Hold
372
﹤0.01% 3912
2022
Q2
$8K Hold
372
﹤0.01% 3873
2022
Q1
$13K Hold
372
﹤0.01% 3749
2021
Q4
$15K Hold
372
﹤0.01% 3652
2021
Q3
$34K Hold
372
﹤0.01% 3273
2021
Q2
$27K Hold
372
﹤0.01% 3350
2021
Q1
$14K Hold
372
﹤0.01% 3534
2020
Q4
$15K Hold
372
﹤0.01% 3439
2020
Q3
$9K Buy
+372
New +$9.61K ﹤0.01% 3526
2018
Q3
Sell
-80
Closed -$13K 4123
2018
Q2
$13K Buy
+80
New +$13.5K ﹤0.01% 3595

Other funds holding CLSD

PNC Financial Services Group's CLSD Position: Q4 2025 in Review

PNC Financial Services Group sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 7,194 shares — an estimated $28.6K sold.

PNC Financial Services Group first reported a position in CLSD in Q2 2018 and held it in 22 quarters. The position peaked at $137K in Q3 2024. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.

  • PNC Financial Services Group reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 7,194 Clearside Biomedical shares in Q4 2025, an estimated $28.6K.
  • PNC Financial Services Group first reported a position in Clearside Biomedical in Q2 2018 and held it in 22 quarters.
  • PNC Financial Services Group's Clearside Biomedical position peaked at $137K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.

Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.